Abstract: The present invention belongs to the technical field of medicines, and particularly relates to a method for synthesizing an anti-tumor compound and intermediates thereof. The synthesis method of the present invention has improved operability and allows for a simplified process, in which higher purity can be achieved without the complicated process of recrystallizing the synthesized target compound, and thus less of the three wastes is produced, making the method more suitable for industrial mass production. Where the intermediates according to the present invention are used for preparing an anti-tumor compound, by-products are effectively reduced during reactions, and thus the overall yield of the reactions are improved, and is at least twice as high as that obtained using the existing synthesis method.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.

Abstract: Disclosed are a TAM family kinase/and Ron kinase inhibitor compound as shown in general formula (I), a pharmaceutically acceptable salt, an ester, a stereoisomer and a tautomer thereof, a pharmaceutical composition and a pharmaceutical preparation containing same, and the use thereof. The compound can selectively inhibit TAM family tyrosine kinase/and Ron kinase, and can be used for the treatment and/or prevention of diseases mediated by the abnormal expression of a receptor of TAM family kinase/and Ron kinase and/or a ligand thereof. By means of targeted inhibition of the TAM family kinase/and Ron kinase, the compound can reverse the immunosuppressive environment in a tumor microenvironment, inhibit the growth, migration and/or drug resistance performance of tumors, and exert anti-tumor immunological effects and anti-tumor efficacy. The definition of each group in the formula is described in the specification.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to a crystal form of a phosphodiesterase inhibitor as shown in formula (I), a preparation method therefor and the use thereof.

Abstract: The present invention relates to the technical field of pharmaceuticals. Specifically, the present invention relates to a halo-allylamine compound, or a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer thereof, and a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, and use in preventing and/or treating a disease related to or mediated by the SSAO/VAP-1 protein, wherein R1, R2, R3, R4, R5, R6, L1 and Cy1 are defined in the specification.

Abstract: The present invention relates to the technical field of pharmaceuticals, and particularly to a PDE9 inhibitor compound of formula (I) or a pharmaceutically acceptable salt or an isomer thereof. The present invention also relates to pharmaceutical formulations, pharmaceutical compositions and use thereof. R1, R2, ring A, L, m and n are defined as in the specification. The compound of the present invention can be used in the manufacture of a medicament for treating or preventing the PDE9-mediated related disease.

Abstract: Provided by the present invention is a novel quinoline derivative inhibitor, which has a structure represented by the following general formula (I). The compound of the present invention may selectively inhibit the TAM family of tyrosine kinases/and CSF1R kinase, and may be used for the treatment and/or prevention of diseases mediated by the abnormal expression of TAM family kinases/and CSF1R kinase receptors and/or ligands thereof. Furthermore, the compound of the present invention may be used to treat and/or prevent related diseases caused by NTRK, more specifically, said compound may be used for the treatment and/or prevention of drug-resistant related diseases caused by NTRK mutations. The definitions of each group are as shown in the description.

Abstract: The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitor activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof.